ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2017
Imaging outcome measures for progressive multiple sclerosis trials.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Are multi-contrast magnetic resonance images necessary for segmenting multiple sclerosis brains? A large cohort study based on deep learning.Magnetic resonance imaging · 2020Trial
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.The New England journal of medicine · 2018Trial
- Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.Neurology · 2026Article
- Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.Journal of neurology · 2025Observational
- Measuring Disease Progression in Multiple Sclerosis Clinical Drug Trials and Impact on Future Patient Care.CNS drugs · 2025Review
- Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Review
- Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.CNS drugs · 2024Review
- Observational
- Quantitative morphometric changes in vascular mild cognitive impairment patients: early diagnosis of dementia.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.Journal of neurology · 2023Observational
- Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis.Frontiers in neurology · 2023Article
- Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina.Arquivos de neuro-psiquiatria · 2022Article
- An in vivo accelerated developmental myelination model for testing promyelinating therapeutics.BMC neuroscience · 2022Article
- Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.Neurology · 2022Article
- Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland.Wellcome open research · 2022Article
- [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].Der Nervenarzt · 2021Review
- Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review.Journal of clinical medicine · 2021Review
- The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
Corrections and comments
- Erratum issuedErratum.2018
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imaging markers that are reliable, reproducible and sensitive to neurodegenerative changes in progressive multiple sclerosis (MS) can enhance the development of new medications with a neuroprotective mode-of-action. Accordingly, in recent years, a considerable number of imaging biomarkers have been included in phase 2 and 3 clinical trials in primary and secondary progressive MS. Brain lesion count and volume are markers of inflammation and demyelination and are important outcomes even in progressive MS trials. Brain and, more recently, spinal cord atrophy are gaining relevance, considering their strong association with disability accrual; ongoing improvements in analysis methods will enhance their applicability in clinical trials, especially for cord atrophy. Advanced magnetic resonance imaging (MRI) techniques (e.g. magnetization transfer ratio (MTR), diffusion tensor imaging (DTI), spectroscopy) have been included in few trials so far and hold promise for the future, as they can reflect specific pathological changes targeted by neuroprotective treatments. Positron emission tomography (PET) and optical coherence tomography have yet to be included. Applications, limitations and future perspectives of these techniques in clinical trials in progressive MS are discussed, with emphasis on measurement sensitivity, reliability and sample size calculation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.